348 related articles for article (PubMed ID: 22711747)
1. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
Zamek-Gliszczynski MJ; Bedwell DW; Bao JQ; Higgins JW
Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
[TBL] [Abstract][Full Text] [Related]
2. Minor compensatory changes in SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats do not detract from their utility in the study of transporter-mediated pharmacokinetics.
Zamek-Gliszczynski MJ; Goldstein KM; Paulman A; Baker TK; Ryan TP
Drug Metab Dispos; 2013 Jun; 41(6):1174-8. PubMed ID: 23569176
[TBL] [Abstract][Full Text] [Related]
3. Brain penetration of WEB 2086 (Apafant) and dantrolene in Mdr1a (P-glycoprotein) and Bcrp knockout rats.
Fuchs H; Kishimoto W; Gansser D; Tanswell P; Ishiguro N
Drug Metab Dispos; 2014 Oct; 42(10):1761-5. PubMed ID: 25053619
[TBL] [Abstract][Full Text] [Related]
4. Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites.
Vlaming ML; Teunissen SF; van de Steeg E; van Esch A; Wagenaar E; Brunsveld L; de Greef TF; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Mol Pharmacol; 2014 Mar; 85(3):520-30. PubMed ID: 24334255
[TBL] [Abstract][Full Text] [Related]
5. Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice.
Tian X; Li J; Zamek-Gliszczynski MJ; Bridges AS; Zhang P; Patel NJ; Raub TJ; Pollack GM; Brouwer KL
Antimicrob Agents Chemother; 2007 Sep; 51(9):3230-4. PubMed ID: 17576841
[TBL] [Abstract][Full Text] [Related]
6. Deletion of Abcg2 has differential effects on excretion and pharmacokinetics of probe substrates in rats.
Huang L; Be X; Tchaparian EH; Colletti AE; Roberts J; Langley M; Ling Y; Wong BK; Jin L
J Pharmacol Exp Ther; 2012 Nov; 343(2):316-24. PubMed ID: 22869929
[TBL] [Abstract][Full Text] [Related]
7. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
8. Differential role of P-glycoprotein and breast cancer resistance protein in drug distribution into brain, CSF and peripheral nerve tissues in rats.
Huang L; Li X; Roberts J; Janosky B; Lin MH
Xenobiotica; 2015; 45(6):547-55. PubMed ID: 25539457
[TBL] [Abstract][Full Text] [Related]
9. Estimating Efflux Transporter-Mediated Disposition of Molecules beyond the Rule of Five (bRo5) Using Transporter Gene Knockout Rats.
Miyake T
Biol Pharm Bull; 2020 Mar; 43(3):384-392. PubMed ID: 31685755
[TBL] [Abstract][Full Text] [Related]
10. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
Zhang S; Wang X; Sagawa K; Morris ME
Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
[TBL] [Abstract][Full Text] [Related]
11. Impact of genetic deficiencies of P-glycoprotein and breast cancer resistance protein on pharmacokinetics of aripiprazole and dehydroaripiprazole.
Nagasaka Y; Sano T; Oda K; Kawamura A; Usui T
Xenobiotica; 2014 Oct; 44(10):926-32. PubMed ID: 24666334
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse.
Zaher H; Khan AA; Palandra J; Brayman TG; Yu L; Ware JA
Mol Pharm; 2006; 3(1):55-61. PubMed ID: 16686369
[TBL] [Abstract][Full Text] [Related]
13. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
[TBL] [Abstract][Full Text] [Related]
14. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.
Lagas JS; Vlaming ML; van Tellingen O; Wagenaar E; Jansen RS; Rosing H; Beijnen JH; Schinkel AH
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6125-32. PubMed ID: 17062689
[TBL] [Abstract][Full Text] [Related]
16. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
[TBL] [Abstract][Full Text] [Related]
17. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
Marchetti S; de Vries NA; Buckle T; Bolijn MJ; van Eijndhoven MA; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
Mol Cancer Ther; 2008 Aug; 7(8):2280-7. PubMed ID: 18723475
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
de Vries NA; Zhao J; Kroon E; Buckle T; Beijnen JH; van Tellingen O
Clin Cancer Res; 2007 Nov; 13(21):6440-9. PubMed ID: 17975156
[TBL] [Abstract][Full Text] [Related]
19. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
Zhou L; Schmidt K; Nelson FR; Zelesky V; Troutman MD; Feng B
Drug Metab Dispos; 2009 May; 37(5):946-55. PubMed ID: 19225039
[TBL] [Abstract][Full Text] [Related]
20. Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice.
Geyer J; Gavrilova O; Petzinger E
J Vet Pharmacol Ther; 2009 Feb; 32(1):87-96. PubMed ID: 19161460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
